Acumen (ABOS) news
Recent news
JCR Pharma: Acumen option to develop candidates for Alzheimer's
Acumen Pharmaceuticals (NASDAQ: ABOS) has entered into a collaboration and option agreement with JCR Pharmaceuticals to develop up to two therapeutic candidates targeting Alzheimer’s disease using JCR’s proprietary J-Brain Cargo® technology platform. The partnership combines Acumen’s expertise in…
AInvest Wire · Jun 17, 2026Acumen Pharmaceuticals exercises exclusive option for up to two Alzheimer's disease candidates with JCR Pharmaceuticals Co
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has exercised its exclusive option to develop up to two Alzheimer’s disease candidates in collaboration with JCR Pharmaceuticals Co., Ltd. (TSE 4552), following the completion of preclinical candidate data in early 2026 as outlined in their strategic…
AInvest Wire · Jun 17, 2026Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $7
Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $7 Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for Alzheimer's disease (AD), has recently caught the…
AInvest Wire · Jul 25, 2024ImportantAcumen plans to start phase 1 of Enhaze & ACU193 in mid-2024
AInvest Wire · Nov 6, 2023ImportantHalozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE Technology in Alzheimer's Disease
Halozyme Therapeutics, Inc. today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous…
AInvest Wire · Nov 6, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.